×
About 459,505 results

I Am CDC - Kimberly Nguyen
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/415944

I joined CDC in 2010, after working for the Connecticut Department of Public Health, because I wanted to protect people’s health in the whole country, not just in one state. Currently, I work for the National Center for Immunization and Respiratory Diseases. We assess child and adult vaccination coverage in the United States. Vaccinations are one of the top ten great public health achievements ...

I Am CDC - Scott Scales
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/415950

Since 2009, I’ve had the pleasure of working at CDC. Before that, I had a 27-year adventure with the United States Army where I was fortunate enough to travel the world, meet the love of my life, and fly some of the world’s best helicopters. At CDC, after two years with the Division of Emergency Operations, I was recommended for a detail assignment to the CDC Office of the Director and was ulti...

I Am CDC Zarecki-Brown-Newsome
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/415951

I’ve been at CDC for 10 years. I work for the National Center on Birth Defects and Developmental Disabilities, leading a project that works to identify the best ways to care for people with spina bifida across the lifespan. I work for the National Center for Injury Prevention and Control where I translate CDC guidance into training materials that educate healthcare providers about safer, more e...

ASL Video Series: When to Get Medical Care for COVID-19
https://tools.cdc.gov/medialibrary/index.aspx#/media/id/407803

When to Get Medical Care for COVID-19 in American Sign Language Comments on this video are allowed in accordance with our comment policy: http://www.cdc.gov/SocialMedia/Tools/CommentPolicy.html This video can also be viewed at https://www.cdc.gov/video/socialmedia/316132-D_ParentsSupportingChildren_COVID19_ASL.mp4

Agenus Withdraws BLA for Balstilimab in Metastatic Cervical Cancer
https://www.onclive.com/view/agenus-withdraws-bla-for-balstilimab-in-metastatic-cervical-cancer

Oct 22nd, 2021 - The immuno-oncology company Agenus has made the decision to withdraw its biologic license application (BLA) for the use of the PD-1 inhibitor balstilimab in patients with recurrent or metastatic cervical cancer who experienced disease progression on, or after, chemotherapy.1 The decision follows the full approval of pembrolizumab (Keytruda) on October 13, 2021, for use as a single agent in pat...

Children With Cancer At Higher Risk for Severe Illness from COVID-19
https://www.onclive.com/view/children-with-cancer-at-higher-risk-for-severe-illness-from-covid-19

Oct 22nd, 2021 - Approximately 20% of pediatric patients with cancer infected with COVID-19 experienced severe illness, according to data published in The Lancet Oncology. Furthermore, deaths due to the infection were proportionally higher in this patient population compared with the general pediatric population, providing evidence that children with cancer are at higher risk of developing severe illness from C...

Oncopeptides Withdraws Melphalan Flufenamide Myeloma Indication in the United States
https://www.onclive.com/view/oncopeptides-withdraws-melphalan-flufenamide-myeloma-indication-in-the-united-states

Oct 22nd, 2021 - Oncopeptides AB (publ) has made the decision to withdraw the indication of melphalan flufenamide (Pepaxto; melflufen) in combination with dexamethasone in select adult patients with relapsed or refractory multiple myeloma from the US market.1 In February 2021, the FDA approved melflufen plus dexamethasone for use in adult patients with relapsed/refractory multiple myeloma who have received at ...

Low androgen in kidney recipients tied to diabetes
https://www.mdedge.com/endocrinology/article/247792/diabetes/low-androgen-kidney-recipients-tied-diabetes
Miriam E. Tucker

Oct 22nd, 2021 - Low androgen levels appear to be linked to the development of posttransplantation diabetes mellitus (PTDM) in male kidney transplant recipients, new research suggests. London_England/Thinkstock Among 243 men who did not have diabetes prior to undergoing kidney transplantation, levels of both dihydrotestosterone (DHT) and testosterone were inversely related to the risk for developing diabetes th.

TAS-102 Plus Bevacizumab Misses PFS End Point in Frontline Unresectable Metastatic CRC
https://www.onclive.com/view/tas-102-plus-bevacizumab-misses-pfs-end-point-in-frontline-unresectable-metastatic-crc

Oct 22nd, 2021 - The frontline combination of trifluridine/tipiracil (TAS-102; Lonsurf) and bevacizumab (Avastin) was not found to result in a significant improvement in progression-free survival (PFS) over capecitabine and bevacizumab in patients with unresectable metastatic colorectal cancer (mCRC) who are not eligible to receive intensive therapy, missing the primary end point of the phase 3 SOLSTICE trial (...

Walmart, Walgreens U.S. stores roll out Moderna, J&J COVID-19 booster shots
https://www.reuters.com/article/health-coronavirus-boosters/update-4-walmart-walgreens-u-s-stores-roll-out-moderna-jj-covid-19-booster-shots-idUSL4N2RI3BC

Oct 22nd, 2021 - (Reuters) -Walgreens Boots Alliance Inc and Walmart Inc said on Friday their U.S. pharmacies started administering COVID-19 booster shots from Moderna Inc and Johnson & Johnson, in addition to previously authorized Pfizer-BioNTech booster. The Centers for Disease Control and Prevention (CDC) on Thursday recommended J&J and Moderna’s booster shots and said Americans can choose a different shot f...

Myeloma Drug Pulled From Market Just Months After Approval
https://www.medpagetoday.com/hematologyoncology/myeloma/95223

Oct 22nd, 2021 - Just months after FDA granted accelerated approval of its myeloma drug, Oncopeptides has pulled melphalan flufenamide (melflufen, Pepaxto) from the market. The decision followed an FDA hold on clinical trials of the drug after data from a confirmatory trial showed an increased mortality risk in patients treated with melflufen. The phase III OCEAN study compared melflufen plus dexamethasone and ...

NSCLC Incidence Declining, Except in Stage I Disease
https://www.medpagetoday.com/radiology/diagnosticradiology/95219

Oct 22nd, 2021 - The overall incidence of non-small cell lung cancer (NSCLC) decreased from 2010 to 2017, with the incidence of stage IV disease falling, and stage I disease rising, researchers determined. A cross-sectional epidemiological analysis showed that NSCLC incidence per 100,000 population declined from 46.4 to 40.9 during the study period. While the incidence of stage II, IIIA, and IIIB disease was st...

Pembrolizumab/Chemo Approved in Europe for Select Locally Recurrent Unresectable or Metastatic TNBC
https://www.onclive.com/view/pembrolizumab-chemo-approved-in-europe-for-select-locally-recurrent-unresectable-or-metastatic-tnbc

Oct 22nd, 2021 - The European Commission has approved pembrolizumab (Keytruda) plus chemotherapy for the frontline treatment of patients with locally recurrent unresectable or metastatic triple-negative breast cancer (TNBC) whose tumors have a PD-L1 expression combined positive score (CPS) of 10 or higher and who have not previously received chemotherapy for metastatic disease.1 The regulatory decision is ba...

Study: Chronic GI Disorders Surfaced Months After COVID
https://www.medpagetoday.com/gastroenterology/irritablebowelsyndrome/95218

Oct 22nd, 2021 - Four in 10 COVID-19 patients from disadvantaged communities developed new post-COVID gastrointestinal disorders, including functional dyspepsia (FD) and irritable bowel syndrome (IBS), researchers found in a retrospective study. In a survey of 200 individuals, 39.5% developed de novo post-COVID gastrointestinal disorders, with 58 reporting FD-like complaints, two reporting IBS-like complaints, ...

HCA Healthcare's labor pains cast shadow on upbeat quarter
https://www.reuters.com/article/hca-healthcare-results/update-4-hca-healthcares-labor-pains-cast-shadow-on-upbeat-quarter-idUSL4N2RI2TL

Oct 22nd, 2021 - (Reuters) -HCA Healthcare Inc on Friday cautioned higher labor costs that tarnished strong third quarter profits could linger for longer as the hospital operator battles a staff crunch, sending the company’s shares down. A nationwide shortage of healthcare workers amid fatigue from a prolonged COVID-19 pandemic has forced hospitals to shell out more to hire and retain nurses and other staff ami...

Burnout a Risk Factor for Suicidal Thoughts in Nurses
https://www.medpagetoday.com/nursing/nursing/95217

Oct 22nd, 2021 - Nurses experiencing burnout were twice as likely to have thoughts of suicide, and those with symptoms of depression were 11 times as likely to experience suicidal thoughts, a survey study found. Among more than 7,000 nurses surveyed from November to December 2017, a total of 5.5% experienced suicidal ideation, which is higher than rates of suicidal thoughts in the general population (4.3%), rep...

A Wealth of Therapeutic Advances in Lung Cancer Stress a Need for Early NGS Testing
https://www.onclive.com/view/a-wealth-of-therapeutic-advances-in-lung-cancer-stress-a-need-for-early-ngs-testing

Oct 22nd, 2021 - The overwhelming number of options for the treatment of patients with lung cancer underscores the importance of broad molecular testing up front to ensure patients receive optimal care, said Stephen V. Liu, MD. Our strategies [for managing lung cancer] are becoming more sophisticated and precise, but the first step of broad next-generation sequencing [NGS] is really the key. NGS is essential t...

FDA Approves Companion Diagnostic for Adjuvant Atezolizumab in Stage II to IIIA NSCLC
https://www.onclive.com/view/fda-approves-companion-diagnostic-for-adjuvant-atezolizumab-in-stage-ii-to-iiia-nsclc

Oct 22nd, 2021 - The FDA has approved the VENTANA PD-L1 (SP263) assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer (NSCLC) whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab (Tecentriq) following surgery and platinum-based chemotherapy.1 Adjuvant atezolizumab was approved for use in this indication on O...

Too Many TAVR Centers Are Clustered Around Well-to-Do Communities
https://www.medpagetoday.com/cardiology/pci/95213

Oct 22nd, 2021 - The proliferation of transcatheter aortic valve replacement (TAVR) programs in the U.S. was largely limited to metropolitan areas and hospitals serving relatively affluent patients, a study found. Only 2% of the 583 hospitals with a TAVR program by the end of 2018 were not located in metropolitan areas, and there was only one rural center. Furthermore, half of new programs established in 2012 t...

Tissue Mapping Center for Cellular Senescence Launched at Yale Cancer Center to Study Human Lymphoid Organs
https://www.onclive.com/view/tissue-mapping-center-for-cellular-senescence-launched-at-yale-cancer-center-to-study-human-lymphoid-organs

Oct 22nd, 2021 - The National Institutes of Health (NIH) has awarded a grant to fund cellular senescence research in lymphoid organs at Yale Cancer Center. The five-year, $6.5 million grant will help generate multiscale molecular and cellular maps of cellular senescence in primary and secondary human lymphoid organs to improve our understanding of cellular senescence in development, aging, and disease, includin...